BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10482440)

  • 21. In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase.
    Duc I; Bonnet P; Duranti V; Cardinali S; Rivière A; De Giovanni A; Shields-Botella J; Barcelo G; Adje N; Carniato D; Lafay J; Pascal JC; Delansorne R
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):537-42. PubMed ID: 12767278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme.
    Ahmed S; Davis PJ; Owen CP
    Drug Des Discov; 1996 Oct; 14(2):91-102. PubMed ID: 9010616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
    Recanatini M; Bisi A; Cavalli A; Belluti F; Gobbi S; Rampa A; Valenti P; Palzer M; Palusczak A; Hartmann RW
    J Med Chem; 2001 Mar; 44(5):672-80. PubMed ID: 11262078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.
    Jagusch C; Negri M; Hille UE; Hu Q; Bartels M; Jahn-Hoffmann K; Pinto-Bazurco Mendieta MA; Rodenwaldt B; Müller-Vieira U; Schmidt D; Lauterbach T; Recanatini M; Cavalli A; Hartmann RW
    Bioorg Med Chem; 2008 Feb; 16(4):1992-2010. PubMed ID: 18061460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial deficiency of 17α-hydroxylase/17,20-lyase caused by a novel missense mutation in the canonical cytochrome heme-interacting motif.
    Rubtsov P; Nizhnik A; Dedov I; Kalinchenko N; Petrov V; Orekhova A; Spirin P; Prassolov V; Tiulpakov A
    Eur J Endocrinol; 2015 May; 172(5):K19-25. PubMed ID: 25650406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase.
    Li JS; Li Y; Son C; Brodie AM
    J Med Chem; 1996 Oct; 39(21):4335-9. PubMed ID: 8863811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
    Patocs A; Liko I; Varga I; Gergics P; Boros A; Futo L; Kun I; Bertalan R; Toth S; Pazmany T; Toth M; Szücs N; Horanyi J; Glaz E; Racz K
    J Steroid Biochem Mol Biol; 2005 Nov; 97(3):257-65. PubMed ID: 16176874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
    Krug SJ; Hu Q; Hartmann RW
    J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17).
    Hartmann RW; Hector M; Wachall BG; Palusczak A; Palzer M; Huch V; Veith M
    J Med Chem; 2000 Nov; 43(23):4437-45. PubMed ID: 11087568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of novel 17-(4'-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring.
    Kovács D; Wölfling J; Szabó N; Szécsi M; Schelz Z; Zupkó I; Frank É
    Eur J Med Chem; 2016 Sep; 120():284-95. PubMed ID: 27209562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of novel 17-triazolyl-androst-5-en-3-ol epimers via Cu(I)-catalyzed azide-alkyne cycloaddition and their inhibitory effect on 17α-hydroxylase/C
    Kiss A; Herman BE; Görbe T; Mernyák E; Molnár B; Wölfling J; Szécsi M; Schneider G
    Steroids; 2018 Jul; 135():79-91. PubMed ID: 29577953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM; Rogers SA; Aubé J; Scott EE
    Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity.
    Tiosano D; Knopf C; Koren I; Levanon N; Hartmann MF; Hochberg Z; Wudy SA
    Eur J Endocrinol; 2008 Mar; 158(3):385-92. PubMed ID: 18299473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
    Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
    J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
    Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
    Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.